MARKET

VVUS

VVUS

VIVUS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.860
+0.060
+2.14%
Closed 16:00 11/15 EST
OPEN
2.900
PREV CLOSE
2.800
HIGH
2.900
LOW
2.822
VOLUME
42.75K
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
2.150
MARKET CAP
30.44M
P/E (TTM)
-1.0330
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VVUS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VVUS News

  • Edited Transcript of VVUS earnings conference call or presentation 5-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1d ago
  • VVUS: Never In a Straight Line
  • Zacks Small Cap Research.5d ago
  • VIVUS, Inc. (VVUS) CEO John Amos on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/06 03:30
  • Vivus EPS misses by $0.30, misses on revenue
  • seekingalpha.11/06 02:09

More

Industry

Pharmaceuticals
+1.37%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About VVUS

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
More

Webull offers VIVUS, Inc. (VVUS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.